Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

FP-1305 (Bexmarilimab) plus Pembrolizumab for the Treatment of Non-Small Cell Lung Cancer

Trial Status: withdrawn

This phase Ib trial tests the safety, side effects, and best dose of FP-1305 (bexmarilimab) in combination with pembrolizumab in treating patients with non-small cell lung cancer (NSCLC). Bexmarilimab is a monoclonal antibody to CLEVER-1 and pembrolizumab is a monoclonal antibody to PD-L1. Immunotherapy with monoclonal antibodies, such as bexmarilimab and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving bexmarilimab in combination with pembrolizumab may have a synergistic (cooperative) effect that could kill more tumor cells in patients with NSCLC.